IRIX
NASDAQIRIDEX Corporation
Price$1.05-0.41 (-28.08%)
2026-01-202026-04-23
News · 26 weeks47-20%
2025-10-262026-04-19
Mix1890d
- Insider10(56%)
- SEC Filings4(22%)
- Other2(11%)
- Earnings2(11%)
Latest news
25 items- PRIridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser TechnologyMOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States. Through this partnership, the 1,800 plus EyeProGPO members can receive preferred pricing on the Iridex PASCAL® laser platform, IQ 532® and IQ 577® lasers, and the OcuLight® TX laser, helping practices, ASCs, and hospitals im
- SECAmendment: SEC Form D/A filed by IRIDEX CorporationD/A - IRIDEX CORP (0001006045) (Filer)
- INSIDERSEC Form 4 filed by Novel Inspiration International Co., Ltd.4 - IRIDEX CORP (0001006045) (Issuer)
- SECSEC Form 10-K filed by IRIDEX Corporation10-K - IRIDEX CORP (0001006045) (Filer)
- SECIRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex Reports Fourth Quarter and Full Year 2025 Financial ResultsMOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl
- SECIRIDEX Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro
- INSIDERChief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,942 worth of shares (2,200 units at $1.34), increasing direct ownership by 2% to 119,890 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,460 worth of shares (1,000 units at $1.46), increasing direct ownership by 0.87% to 116,190 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- PRIridex Announces Plans to Relocate HeadquartersMOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the "Lease"). The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized b
- INSIDERChief Financial Officer Dizon Romeo R bought $1,588 worth of shares (1,101 units at $1.44), increasing direct ownership by 0.99% to 112,690 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,898 worth of shares (1,300 units at $1.46), increasing direct ownership by 1% to 111,589 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $5,009 worth of shares (3,385 units at $1.48), increasing direct ownership by 3% to 110,289 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,889 worth of shares (1,243 units at $1.52), increasing direct ownership by 1% to 106,904 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $7,716 worth of shares (5,221 units at $1.48), increasing direct ownership by 5% to 105,661 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $6,381 worth of shares (4,259 units at $1.50), increasing direct ownership by 4% to 100,440 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $5,006 worth of shares (3,496 units at $1.43), increasing direct ownership by 4% to 96,181 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECIRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%Achieved positive cash flow in the fourth quarterSold 15,800 Cyclo G6® probes compared to 13
- INSIDERLarge owner Novel Inspiration International Co., Ltd. acquired 116,540 shares (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERLarge owner Novel Inspiration International Co., Ltd. acquired 97,610 shares (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)